Human TROP-2/TACSTD2 Protein
Catalog No: TROP2-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human TROP-2/TACSTD2 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues His27-Thr274 (UniProt accession: P09758).
Product Details
- Molecular Aliases
- EGP1; EGP-1; TROP2; GA733-1; gp50; T16; TACSTD2; TROP-2; M1S1; TACD2
- Protein Length
- His27-Thr274
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 54.6 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human TROP-2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human TROP-2 is greater than 95% as determined by SEC-HPLC.
Immobilized Human TROP-2, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-TROP-2 Antibody, hFc Tag with the EC50 of 6.7ng/ml determined by ELISA.
Background
Trop-2,also known as epithelial glycoprotein-1 antigen (EGP-1),is a protein that in humans is encoded by the TACSTD2 gene.Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.
References
- Goldenberg D M, Cardillo T M, Govindan S V, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*[J]. Oncotarget, 2015, 6(26). Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.